Two different preparations, solution and suspension, of three benzimidazole carbamate drugs, mebendazole, albendazole and ricobendazole, were compared by analyzing their in vivo activity against Echinococcus granulosus cysts in a mouse model. Polyvinylpyrrolidone was used for the elaboration of drug solutions and these formulations manifested better results in terms of reduction of number of viable hydatid cysts in mice than the reference drug suspensions. The effect was more prominent on mebendazole-treated mice, at doses of 25-50 mg/kg. There was a correlation between ED50 and pharmacokinetical parameters of AUC0 and CMAX, showing that a significant improvement on solubility affects the in vivo activity of these drugs.
There is not a defi nitive chemotherapy available already (Carpio et al, 1995) , and surgery is the standar treatment. The drugs usually used for anti-hydatid cyst treatment are benzi midazole carbamate derivatives such as mebendazole (MBZ), albendazole (ABZ) and its active metabolite commercialized as ricobendazole (RBZ). They have limited solubility and therefore poor absorption following oral administration (Da Silva et al, 1997) . Despite this, they are extensively used in hydatid disease, although long-term treatments are usually required and adverse side effects and failed results may occur (El-On, 2003 (Cotting et al, 1990 ) the solution formulations should provide better bioavailability than the conventional drug suspensions. Thus, the intention of the present study is to carry out comparative and analytical studies of different formu lations of ABZ, RBZ and MBZ in an in vivo mouse model. weight. PVP-dispersed drugs were dissolved in distilled water. The reference drugs were suspended in 1 % carboxymethylcellulose (CMC).
MATERIAL AND METHODS

D
Twenty five to forty days old female NMRI mice were infected by i.p. injection of 2,000 protoscoleces of sheep origin in 0.5 ml of Hank's Balance Salt Solution.
Eight to ten months post infection, mice were divided into 21 groups of 10 mice each: blank control, CMC control, PVP control, and a group for each of the drugformulation-dose combinations. Except for the blank control group, the preparations (CMC or PVP with/ without drugs at the appropriate concentration) were respectively administered by gavage (0.5 ml at 12 hours intervals; 1 ml/day in total) during two regimes of five consecutive days with a two days break in between.
Drugs effect was evaluated 30 days post-treatment.
Mice were sacrificed by anaesthesia with diethyl-ether Table I . -Correlation between in vivo pharmacokinetical parameters and drug activities (ED50) against Echinococcus granulosus cysts in mice. The asterisk denotes that correlation is statistically significant (p < 0.05).
both formulations, with an increased efficacy when in PVP respect to CMC at both doses. Table I Although this result should be expected against tissue parasites, they were not observed by López et al. (1997) 
